BioSphere: New data shows efficacy, durability of uterine fibroid embolization

SAN FRANCISCO, Jan. 2, 2008 (Thomson Financial delivered by Newstex) -- BioSphere Medical Inc. (NASDAQ:BSMD) said Wednesday that new, three-year data demonstrated that uterine fibroid embolization produced a high level of durable long-term symptom control and resulted in a 'significant improvement' in a woman's health-related quality of life.'Three-year data from the largest, multi-center, prospective voluntary registry on any procedure for benign uterine fibroids showed that 90% of the women participating avoided a hysterectomy, and of these, 85% had a substantial improvement in symptoms and quality of life,' the Society of Interventional Radiology said in a statement.The data is from the Fibroid Registry published in the January 2008 issue of Obstetrics & Gynecology, BioSphere said.The study was funded through the Society for Interventional Radiology Foundation and, in part, from BioSphere, the company noted.

full article >> http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-21990628.htm